Equity Profile

LEGN

Legend Biotech Corporation

Health CareBiotechnology$5.0B

Dec1Thu

Pre-Earnings Brief

UpcomingQ2-2024After Close5:00 PM EST

Company Snapshot

Legend Biotech Corporation is a biotechnology company focused on developing innovative cell therapies for cancer treatment. As part of the health care sector, its advancements in biotechnology could significantly impact patient care and treatment options in oncology.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q2-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

In Q1-2024, Legend Biotech reported an EPS of -$0.16, which was better than the expected -$0.29, resulting in a positive surprise of 44.44%. However, there was no revenue reported against estimates, and the stock reacted negatively the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Legend Biotech's upcoming earnings are mixed, with uncertainty surrounding revenue and clinical trial outcomes. Investors will be keen to see if the company can continue its trend of beating EPS estimates.

Bull Case

The optimistic view hinges on the company reporting better-than-expected EPS and providing positive updates on clinical trials, which could drive the stock price higher.

Bear Case

Conversely, if the company fails to meet expectations on EPS or provides disappointing updates on its clinical trials, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2024, and how does it compare to analyst expectations?

The EPS figure will be crucial in determining the company's profitability and could influence investor confidence.

What updates will be provided on ongoing clinical trials and their expected timelines?

Progress in clinical trials is vital for the company's future growth and can significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Legend Biotech to exceed EPS expectations based on recent clinical trial advancements that have not been fully reflected in analyst models.

Supporting Evidence

The company has a history of beating EPS estimates, with a 67% success rate over the last six quarters.

Options pricing indicates a larger expected move than historical averages, suggesting that investors anticipate significant news.

Recent positive developments in the biotech sector could bode well for Legend Biotech's upcoming results.

Key Risk

If clinical trial updates reveal promising results, it could significantly shift investor sentiment and expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will help determine the company's trajectory amidst ongoing developments in its clinical pipeline.

Bull Confirmed If

A reported EPS of $-0.10 or better, along with positive updates on clinical trials, would confirm the bull case.

Bear Confirmed If

An EPS worse than $-0.20 or negative news on clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.82%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±14.8% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

85.1%

Calls (20K)P/C Ratio: 0.10Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations, history suggests the stock could rise by about 1.71% on the following day, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious investor sentiment.

Miss

A miss could lead to a decline of around 6.91%, as seen in past performance when expectations were not met.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific guidance on expected timelines for clinical trial results.
2Updates on partnerships or collaborations that could enhance product development.
3Details on market demand for their therapies and any new customer acquisitions.
4Management's outlook on future revenue growth and profitability.
5Responses to questions regarding competitive pressures in the biotechnology space.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Elbit Systems Ltd.

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q2-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

The optimistic view hinges on the company reporting better-than-expected EPS and providing positive updates on clinical trials, which could drive the stock price higher.

Bear Case

Conversely, if the company fails to meet expectations on EPS or provides disappointing updates on its clinical trials, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2024, and how does it compare to analyst expectations?

The EPS figure will be crucial in determining the company's profitability and could influence investor confidence.

What updates will be provided on ongoing clinical trials and their expected timelines?

Progress in clinical trials is vital for the company's future growth and can significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Legend Biotech to exceed EPS expectations based on recent clinical trial advancements that have not been fully reflected in analyst models.

Supporting Evidence

The company has a history of beating EPS estimates, with a 67% success rate over the last six quarters.

Options pricing indicates a larger expected move than historical averages, suggesting that investors anticipate significant news.

Recent positive developments in the biotech sector could bode well for Legend Biotech's upcoming results.

Key Risk

If clinical trial updates reveal promising results, it could significantly shift investor sentiment and expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will help determine the company's trajectory amidst ongoing developments in its clinical pipeline.

Bull Confirmed If

A reported EPS of $-0.10 or better, along with positive updates on clinical trials, would confirm the bull case.

Bear Confirmed If

An EPS worse than $-0.20 or negative news on clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.82%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±14.8% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

85.1%

Calls (20K)P/C Ratio: 0.10Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations, history suggests the stock could rise by about 1.71% on the following day, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious investor sentiment.

Miss

A miss could lead to a decline of around 6.91%, as seen in past performance when expectations were not met.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific guidance on expected timelines for clinical trial results.
2Updates on partnerships or collaborations that could enhance product development.
3Details on market demand for their therapies and any new customer acquisitions.
4Management's outlook on future revenue growth and profitability.
5Responses to questions regarding competitive pressures in the biotechnology space.